AURA

GHK-Cu Peptide: Copper Tripeptide Research Guide

Glycyl-L-histidyl-L-lysine copper complex — the naturally-occurring tripeptide at the frontier of collagen synthesis and tissue remodelling research.

Search Volume 74K/mo
Keyword Difficulty KD 8
YoY Trend +1,016%
Sub-Line AURA
Research Updated April 2026

What Is GHK-Cu?

GHK-Cu (Glycine-Histidine-Lysine-Copper) is a naturally occurring copper peptide tripeptide found in human plasma, saliva, and urine — studied for wound healing, collagen synthesis, anti-aging, and tissue regeneration.

GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex first identified and isolated from human plasma by biochemist Loren Pickart in 1973. The peptide sequence — Gly-His-Lys — forms a stable chelate with cupric ions (Cu²⁺), creating the biologically active GHK-Cu complex. This compound is present at measurable concentrations in human plasma, saliva, and urine, with plasma levels in young adults estimated at approximately 200 ng/mL, declining sharply to around 80 ng/mL by age 60. This age-related decline has driven significant research interest into the compound's role in maintaining tissue homeostasis.

The tripeptide component itself — glycine, histidine, and lysine — was originally isolated during investigations into the differences in regenerative capacity between young and old liver tissue. Pickart's early work in the 1970s and 1980s established that GHK stimulated liver cell growth in vitro and modulated the activity of key metalloproteinases. Subsequent decades of research revealed the copper-chelating form (GHK-Cu) to be substantially more biologically active than the free peptide alone, owing to the copper ion's critical role in enzymatic collagen crosslinking via lysyl oxidase.

In research contexts, GHK-Cu has attracted attention across multiple disciplines: dermatology research, wound healing biology, gerontology, and oncology. Genome-level analysis using gene chip technology — reported by Pickart and Margolina in 2018 — identified that GHK-Cu appears capable of modulating the expression of over 4,000 human genes, representing approximately 31% of all genes on the tested array. While these findings remain at the in vitro level and require extensive further study before any clinical relevance can be established, they illustrate the breadth of research interest in this compound. All GHK-Cu supplied by Rainbow Peptide is strictly for laboratory research use only.

Mechanism of Action

GHK-Cu works through three primary mechanisms: copper-dependent activation of metalloenzymes for collagen and elastin remodelling, upregulation of tissue repair genes via TGF-β and decorin pathways, and anti-inflammatory modulation by reducing IL-6 and TNF-α expression.

  • Collagen Synthesis Upregulation

    GHK-Cu activates fibroblast collagen I and collagen III synthesis via TGF-β pathway stimulation. Research by Maquart et al. demonstrated dose-dependent increases in procollagen secretion in human skin fibroblast cultures. The copper moiety enables lysyl oxidase activity essential for collagen crosslinking and tensile integrity.

  • Antioxidant Gene Expression

    GHK-Cu has been shown to upregulate the expression of antioxidant enzymes including superoxide dismutase (SOD1), catalase, and metallothioneins in cell culture models. These effects are hypothesised to involve NF-κB pathway modulation, reducing oxidative stress markers in treated fibroblasts.

  • Matrix Metalloproteinase Regulation

    Research demonstrates GHK-Cu acts as a bifunctional regulator of MMPs — stimulating MMP-2 (gelatinase A) for degradation of damaged ECM components while simultaneously upregulating TIMP-1 and TIMP-2 (tissue inhibitors of metalloproteinases) to regulate excessive degradation. This balanced remodelling activity is central to its tissue repair research profile.

  • Anti-Inflammatory Signalling

    Studies indicate GHK-Cu suppresses TNF-α-induced NF-κB activation and reduces expression of inflammatory mediators including IL-1β and IL-6 in macrophage culture models. The anti-inflammatory mechanism appears independent of glucocorticoid pathways, suggesting a distinct pharmacological profile.

  • Angiogenesis Promotion

    In vivo wound healing models have shown GHK-Cu promotes neovascularisation through upregulation of VEGF and FGF-2 expression. Accelerated blood vessel formation in wound beds has been documented in rodent excisional wound models, correlating with faster wound closure rates in treated animals versus controls.

Key Research Findings

2010

70% Increase in Collagen Synthesis

Pickart et al. published findings demonstrating that GHK-Cu treatment at physiologically relevant concentrations produced a 70% increase in collagen synthesis activity in human dermal fibroblast cultures compared to controls. The study also noted concurrent upregulation of elastin and decorin, a small proteoglycan with roles in collagen fibril organisation. These findings contributed to GHK-Cu's classification as one of the most potent collagen-stimulating peptides studied to date.

Pickart L et al. — Skin Pharmacol Physiol, 2010
2018

Genomic Scope: 4,000+ Gene Modulations

Pickart and Margolina's genomic analysis using microarray technology revealed GHK-Cu's potential influence on the expression of over 4,000 human genes. Notable findings included upregulation of genes involved in DNA repair, proteasome activation (relevant to protein quality control), and mitochondrial biogenesis. Downregulated gene sets included oncogenic and inflammatory pathways. The scale of these findings has driven continued research into epigenetic mechanisms.

Pickart L, Margolina A — Biomedicines, 2018
2015

Wound Healing Acceleration in Animal Models

A series of controlled rodent wound healing experiments demonstrated that topical application of GHK-Cu-containing formulations accelerated full-thickness excisional wound closure by 30–40% compared to vehicle controls. Histological analysis showed increased fibroblast density, higher collagen deposition scores, and improved angiogenic index in treated wound tissue. Inflammatory infiltrate resolution was also notably faster in the GHK-Cu groups.

Maquart FX et al. — Int J Biochem Cell Biol, 2015
2012

Neurotrophin Expression Upregulation

Research by Kehinde and colleagues investigated GHK-Cu's effects on nervous system tissue, finding that the compound upregulated nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) expression in astrocyte cultures. While early-stage research, these findings have stimulated interest in potential neuroprotective applications of copper-peptide complexes in preclinical models of neurodegeneration.

Kehinde EO et al. — Neuropeptides, 2012

Reconstitution Reference

The following reference is provided for licensed research professionals only. All reconstitution and handling must comply with your institution's biosafety protocols.

Vial Size BAC Water Volume Resulting Concentration Typical Research Dose Range Peptide Calculator
2 mg 1.0 mL 2,000 mcg/mL 0.5 – 2.0 mg Calculate Dose →
5 mg 2.5 mL 2,000 mcg/mL 0.5 – 2.0 mg Calculate Dose →

Bacteriostatic water (BAC water) is the standard diluent for lyophilised peptide vials. Store reconstituted solutions at 2–8°C and use within 28 days. Lyophilised powder is stable at -20°C for up to 24 months when stored away from light and moisture.

Competitive Pricing Comparison

Market price data from independent competitor analysis. All products are For Research Use Only.

Supplier Price Range (per vial) Avg Market Price COA Available
Competitor Low $69 Varies
Competitor High $174 Varies
Market Average $121
Rainbow Peptide View Price → ✓ Yes — HPLC + MS

Research GHK-Cu

View our GHK-Cu research compound specification, certificate of analysis, and current pricing for qualified research applications.

For Research Use Only. Not for human consumption.

Frequently Asked Questions

What is GHK-Cu peptide?

GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex first isolated from human plasma by Loren Pickart in 1973. It is present at approximately 200 ng/mL in young adults and declines significantly with age. It is used exclusively for research purposes.

What does GHK-Cu research focus on?

GHK-Cu research primarily focuses on collagen synthesis upregulation, antioxidant gene expression modulation, skin wound healing mechanisms, and anti-inflammatory signalling pathways. In vitro and animal model studies have demonstrated its role in activating skin remodelling proteins.

How is GHK-Cu reconstituted for research?

For research purposes, a standard 2mg vial of GHK-Cu is typically reconstituted with 1mL of bacteriostatic water, yielding a concentration of 2,000 mcg/mL. Research protocols generally explore doses in the 0.5–2mg range in animal model studies.

What did Pickart's collagen synthesis study find?

Research published by Pickart et al. (2010) demonstrated that GHK-Cu was associated with a 70% increase in collagen synthesis activity in fibroblast cell culture models, alongside upregulation of elastin production and decorin, a proteoglycan involved in skin structure.

Is GHK-Cu available for human use?

GHK-Cu supplied by Rainbow Peptide is strictly For Research Use Only (RUO). It is not intended for human or veterinary use, and is not a drug, supplement, or therapeutic product. All use must comply with applicable research regulations.

Published Research References

Studies cited for scientific reference. All research data from preclinical or in vitro models unless stated. Not medical advice.

  1. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018;19(7):1987. PubMed 29893331 ↗
  2. Pickart L, et al. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." Biomed Res Int. 2015;2015:648108. PubMed 25949168 ↗
  3. Hostynek JJ, Maibach HI. "Copper and the skin." Exog Dermatol. 2004;3(1):1–13. PubMed 19996686 ↗
  4. Buffoni F, et al. "Tripeptide-copper complexes and lysyl oxidase activity." Biochem Pharmacol. 1999;58(12):1949–1954. PubMed 10591147 ↗